A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
Clinical trial NCT04976322 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT04976322
- Sponsor
- UCB Biopharma SRL
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-27
- Primary completion
- 2030-08-07
- Enrollment
- 760
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.